Gene Therapy R&D market is projected to grow at a CAGR of 29.8% by 2034: Visiongain [Yahoo! Finance]
Benitec Biopharma Inc. (BNTC)
US:NASDAQ Investor Relations:
benitec.com/for-investors/investor-faqs
Company Research
Source: Yahoo! Finance
Diseases (Oncologic, Non-oncologic), Cardiovascular Diseases, Ophthalmic Diseases, Haematology, Neurological, Diabetes Mellitus, Other)), by Vector (Viral (Retrovirus, Adenovirus, AAV, Lentivirus, Others), Non-viral (Naked DNA, Gene Gun, Electroporation, Lipofection)), by Techniques (Gene Augmentation Therapy, Gene Replacement Therapy), by Participants (Small/Medium Pharma & Biotech, Universities & Research Institutes, Hospitals, Government & Public Bodies, Big Pharma) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis The gene therapy R&D market is estimated at US$3,641.7 million in 2024 and is projected to grow at a CAGR of 29.8% during the forecast period 2024-2034. Gene Therapy: Shaping Tomorrow's Healthcare Landscape Through Innovation and Investment Over the past five years, gene therapy has seen a remarkable resurgence fuelled by significant strides in virology, vector and capsid architect
Show less
Read more
Impact Snapshot
Event Time:
BNTC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BNTC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BNTC alerts
High impacting Benitec Biopharma Inc. news events
Weekly update
A roundup of the hottest topics
BNTC
News
- Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational UpdateGlobeNewswire
- Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle SocietyGlobeNewswire
- Benitec Biopharma CEO to Participate in OPMD Awareness Day WebinarGlobeNewswire
- Benitec Biopharma Inc. (NASDAQ: BNTC) is now covered by analysts at Guggenheim. They set a "buy" rating and a $17.00 price target on the stock.MarketBeat
- Benitec Biopharma Inc. (NASDAQ: BNTC) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.MarketBeat
BNTC
Sec Filings
- 9/26/24 - Form 8-K
- 9/26/24 - Form 10-K
- 9/5/24 - Form 8-K
- BNTC's page on the SEC website